Gland Pharma Limited – FDA 483, Jun 22, 2015
An FDA inspection of Gland Pharma Ltd. in Visakhapatnam, India, identified multiple significant deficiencies across its pharmaceutical manufacturing operations. Observations included inadequate media fill validation, unvalidated sterilization processes for Restricted Access Barrier systems, poor control over equipment access, and failures in environmental monitoring and alarm management. The firm also lacked proper qualification for a microbiological AutoReader, initiated stability studies late without justification, and performed manual HPLC data integration without written procedures, indicating systemic issues with quality control and adherence to good manufacturing practices.
ID · 68a73223-4d49-4e04-a051-2a216208acda
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.